The Latest Breaking News from MRK

Market sentiment was mostly unchanged on Monday, as investors await the May inflation report. Given the market uncertainties, we think investing in high-yielding dividend stocks that are part of the Dow Jones index—commonly known as the Dogs of the Dow—might the ideal strategy now. And our top choices among these…

Merck & Co Inc (NYSE:MRK) and Ridgeback Biotherapeutics announced that the Annals of Internal Medicine had published additional data from the Phase 3 MOVe-OUT trial of Lagevrio (molnupiravir) in non-hospitalized COVID-19 patients at high risk for progressing to severe disease. A lower proportion of molnupiravir-treated participants in the modified intent-to-treat population had an acute care…

A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 14 strange trades.

The stock market closed the last trading session of May in the red, underscoring inflation fears and rising oil prices. Furthermore, strategists expect the broad market to decline further, given the inflationary pressures and the Fed’s monetary tightening. Hence, we think stocks that have outpaced the broader market so far…

The Fed’s aggressive interest rate increases to tame multi-decade high inflation, and an anticipated economic slowdown, have exacerbated market volatility of late. To protect against the market uncertainties, we think investors should consider investing in low-beta stocks Merck (MRK), Gilead Sciences (GILD), and AmerisourceBergen (ABC). Let’s discuss why.

European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending Merck & Co Inc (NYSE:MRK) Keytruda in melanoma setting. The opinion covers Keytruda as a monotherapy adjuvant treatment for adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have…

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Given current market volatility due to concerns over the Fed's tighter monetary policy to tame surging inflation and fears of an economic slowdown, we think investors should consider buying stocks with sound fundamentals and solid growth attributes. Nutrien (NTR), Merck & Co (MRK), and Bunge (BG) recently reported promising quarterly…

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

The S&P 500 experienced its worst period since 1939 between January and April this year. The stock market has been under pressure due to investor fears about looming interest rate increases, geopolitical tensions, and rising inflation. Hence, we think it might be best now to bet on fundamentally sound stocks…

Over the past 3 months, 7 analysts have published their opinion on Merck & Co (NYSE:MRK) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.